[article] 
inAutism > 11-1 (January 2007) . - p.29-41

Titre :	A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism
Type de document :	Texte imprimé et/ou numérique
Auteurs :	Cooper R. WOODARD, Auteur ; June GRODEN, Auteur ; Matthew GOODWIN, Auteur ; James W. BODFISH, Auteur
Année de publication :	2007
Article en page(s) :	p.29-41
Langues :	Anglais (eng)
Mots-clés :	Autism Dextromethorphan Treatment
Index. décimale :	PER Périodiques
Résumé :	We used a mixed group/single-case, double-blind, placebo-controlled, ABAB design to examine the safety and efficacy of the glutamate antagonist dextromethorphan for the treatment of problematic behaviors and core symptoms in eight children diagnosed with autism. All participants had increased levels of irritability at baseline as measured by the Aberrant Behavior Checklist, and demonstrated a wide variety of problematic behaviors. Group analyses revealed that dextromethorphan was equivalent to placebo in the treatment of problem behaviors and core symptoms. Analyses at the single-subject level demonstrated that three of the eight participants who had a behavioral profile consistent with attention-deficit hyperactivity disorder responded positively to dextromethorphan. Future research that employs a larger, more homogeneous sample is necessary to replicate the findings from this study.
En ligne :	http://dx.doi.org/10.1177/1362361307070989
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=575

[article] A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism [Texte imprimé et/ou numérique] / Cooper R. WOODARD, Auteur ; June GRODEN, Auteur ; Matthew GOODWIN, Auteur ; James W. BODFISH, Auteur . - 2007 . - p.29-41.
Langues : Anglais (eng)
in Autism > 11-1 (January 2007) . - p.29-41

Mots-clés :	Autism Dextromethorphan Treatment
Index. décimale :	PER Périodiques
Résumé :	We used a mixed group/single-case, double-blind, placebo-controlled, ABAB design to examine the safety and efficacy of the glutamate antagonist dextromethorphan for the treatment of problematic behaviors and core symptoms in eight children diagnosed with autism. All participants had increased levels of irritability at baseline as measured by the Aberrant Behavior Checklist, and demonstrated a wide variety of problematic behaviors. Group analyses revealed that dextromethorphan was equivalent to placebo in the treatment of problem behaviors and core symptoms. Analyses at the single-subject level demonstrated that three of the eight participants who had a behavioral profile consistent with attention-deficit hyperactivity disorder responded positively to dextromethorphan. Future research that employs a larger, more homogeneous sample is necessary to replicate the findings from this study.
En ligne :	http://dx.doi.org/10.1177/1362361307070989
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=575